Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX

Transplantation. 2012 Feb 15;93(3):331-6. doi: 10.1097/TP.0b013e31823f7f68.

Abstract

Background: Osteoporosis is a common complication in long-term survivors after liver transplantation (LTX). This study investigates the influence of a combination therapy of low dose parenteral ibandronate (IBN) and calcitriol on top of calcium and vitamin D supplementation in such patients.

Methods: For 3 years, 30 osteoporotic patients after LTX (28±6 months) were treated with quarterly 2 mg IBN intravenously and daily calcitriol (0.25-1.0 μg) on top of 1000 mg calcium and 800 IU vitamin D. Recipients with normal bone density (n=24) were enrolled as controls. Laboratory analysis and dual energy X-ray absorptiometry were performed at baseline and every 12 months. Primary endpoints were changes in bone mineral density and fracture incidence.

Results: IBN patients showed a significant increase of bone mineral density at the femoral neck and the trochanteric region (13% and 15%, respectively, both P=0.001) as compared with baseline whereas the control group revealed a small but significant loss of -5.0% in the trochanteric and -4.9% in the neck region (P<0.05) over the same time period. Fracture incidence was low among IBN patients (7%); however, 23% of the control patients sustained at least one vertebral fracture. The relative fracture risk was 3.21 for IBN patients (95% confidence interval, 0.6-20.9, P=0.03) resulting in an absolute risk reduction for a new vertebral fracture of 14%.

Conclusion: In LTX recipients with osteoporosis combination therapy with low dose IBN and calcitriol on top of calcium and vitamin D supplementation is an effective treatment option.

MeSH terms

  • Alkaline Phosphatase / blood
  • Bone Density
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Remodeling / drug effects*
  • Calcitriol / administration & dosage*
  • Diphosphonates / administration & dosage*
  • Drug Therapy, Combination
  • Female
  • Fractures, Bone / prevention & control*
  • Humans
  • Ibandronic Acid
  • Liver Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Osteoporosis / drug therapy*
  • Parathyroid Hormone / blood
  • Risk

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Parathyroid Hormone
  • Alkaline Phosphatase
  • Calcitriol
  • Ibandronic Acid